Paper Details

  1. Home
  2. Paper Details

Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer.

Author: CaoLi, ChengYan-Qiong, CuiXin-Gang, DaiLi-He, DongKe-Qin, GaoXu, HuangHai, KongDe-Pei, LiuDan, LiuFei, PengGuang, QuMin, SunYing-Hao, TianQin-Qin, WangChao, WangHong-Ru, WangKai-Jian, XuChuan-Liang, XuDan-Feng, YangJun, ZhouZhe, ZhuFeng

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Androgen deprivation therapy (ADT), including enzalutamide, can induce resistance in prostate cancer. This study investigated the association between enzalutamide-induced neuroendocrine differentiation (NED) and tumor-associated macrophages (TAMs). The study found that enzalutamide-induced HMGB1 expression facilitated TAM recruitment and polarization, driving NED via β-catenin stabilization. Combined inhibition of IL6R and HMGB1 may be a potential treatment for enzalutamide resistance.
Paper Details　
Original Abstract of the Article :
<b>Purpose:</b> Androgen deprivation therapy (ADT), including enzalutamide, induces resistance in prostate cancer; ADT resistance is associated with neuroendocrine differentiation (NED) and tumor-associated macrophages (TAM). This study aimed to investigate the association between enzalutamide-indu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1158/1078-0432.CCR-17-2446

データ提供：米国国立医学図書館（NLM）

Enzalutamide Resistance: A Feedback Loop between NED and TAMs

Prostate cancer is a common malignancy that can be challenging to treat. Enzalutamide is a medication used to treat advanced prostate cancer, but resistance to enzalutamide can develop. This article, published in Clinical Cancer Research, investigates the mechanisms underlying enzalutamide resistance, focusing on the interplay between neuroendocrine differentiation (NED) and tumor-associated macrophages (TAMs).

Enzalutamide Resistance: A Complex Interplay

The study found that enzalutamide can induce NED in prostate cancer cells, which is associated with resistance to the medication. The researchers also found that enzalutamide promotes the recruitment and activation of TAMs, which in turn contribute to NED. These findings suggest that a feedback loop exists between NED and TAMs, driving enzalutamide resistance.

Targeting the Feedback Loop: A Novel Therapeutic Strategy

The study highlights the potential of targeting the feedback loop between NED and TAMs as a novel therapeutic strategy for overcoming enzalutamide resistance. The authors propose that inhibiting the signaling pathways involved in this feedback loop, such as the IL6/STAT3 pathway, could potentially enhance the effectiveness of enzalutamide therapy. This approach could lead to improved treatment outcomes for patients with advanced prostate cancer.

Dr. Camel's Conclusion

The human body is a complex ecosystem, and cancer cells can adapt and evolve in response to treatment. This study unravels a fascinating feedback loop that drives resistance to enzalutamide in prostate cancer, offering a novel target for therapeutic intervention. Like a camel navigating a shifting desert landscape, researchers are constantly seeking new ways to outsmart cancer. This study provides a promising avenue for future research and development of more effective treatments for prostate cancer.

Date :
  1. Date Completed 2019-07-24
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

29191973

DOI: Digital Object Identifier

10.1158/1078-0432.CCR-17-2446

Related Literature

Article Analysis
・Effects of enzalutamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.